Casaasdas

Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor

Por um escritor misterioso
Last updated 21 setembro 2024
Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor
Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor
Disease Activity Cutoff Values in Initiating Tumor Necrosis Factor
Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor
Underweight and obesity are strong predictors of clinical outcomes
Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor
Microvascular dysfunction in ankylosing spondylitis is associated
Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor
Long-Term Adherence to Etanercept in Treatment Effectiveness of
Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor
Sub-analysis of predictors of clinical remission achievement
Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor
Long noncoding RNA intersectin 1-2 gradually declines during
Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor
Physical Function and Spinal Mobility Remain Stable Despite
Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor
Mean (A) ASDAS and (B) BASDAI up to Week 48. Safety Set (N=89
Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor
Ankylosing spondylitis disease activity score is related to NSAID
Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor
Comparison of disease activity in patients with ankylosing
Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor
ASAS-EULAR recommendations for the management of axial
Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor
Treatment Failure in Axial Spondyloarthritis: Insights for a
Recomendado para você
você pode gostar

© 2014-2024 citytv24.com. All rights reserved.